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ABSTRACT
Sexual functioning is associated with symptoms of depression, which occurs at rates much
higher than that in the general population. Treatment of depression and remission of depressive
symptoms can improve sexual functioning; however, antidepressants and other medications may
cause or worsen sexual functioning. Assessment of sexual dysfunction in the past has
predominantly relied on the patient spontaneously reporting problems with sexual functioning to
their physician or other medical professional. Due to the sensitive nature of the topic, patient
reporting is typically low and does not reflect the actual prevalence of sexual dysfunction. This
research assessed the rate and level of antidepressant treatment-associated sexual dysfunction as
assessed by validated questionnaire in published and unpublished data.
Studies eligible for inclusion were randomized, double-blind, placebo-controlled trials
evaluating the antidepressant effect in patients with acute major depression. Studies must have
included approved antidepressants evaluating doses in the therapeutic range and include a
validated questionnaire to assess sexual functioning, i.e., the ASEX or CSFQ. The studies must
have included sufficient data to calculated mean standardized effect sizes and/or odds ratios for
developing sexual dysfunction.
The initial search yielded 320 records. After review for eligibility and completeness, the
searched yielded 17 studies for inclusion in this meta-analysis. Sexual dysfunction odds ratios
and standardized mean effect sizes for antidepressant versus placebo were calculated. Where
available, odds ratios and mean effect sizes were also calculated by sex.
viii

The odds of developing sexual dysfunction with paroxetine, escitalopram and duloxetine
were significantly worse than placebo. Evaluation by gender indicated that for women the odds
of developing sexual dysfunction with desvenlafaxine was also significantly worse than placebo.
Standardized mean effect sizes indicated significantly worse sexual functioning versus placebo
for escitalopram and paroxetine with both sexes combined. Significant differences were also
found for men taking vilazodone. Conclusions of this meta-analysis are limited by the number of
studies included. For some antidepressants there was only one study that qualified. Not all
studies provided data by sex. Gender effects are apparent with some antidepressants, so this data
is of particular interest when evaluating the risk of developing sexual dysfunction.
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CHAPTER ONE
OVERVIEW
Sexual dysfunction is a disruption in the normal sexual response cycle and typically affects the
desire, arousal, and/or orgasm phase(s). Sexual dysfunction occurs in approximately one-third of
the general population; however, the prevalence increases with certain comorbid conditions.
Several factors that contribute to the level of dysfunction are: medical illnesses, such as, obesity,
diabetes, cardiovascular disease, sexually transmitted diseases, and urinary tract infection;
alcohol consumption; substance abuse; social status; sexual trauma; medications; emotional
issues; and psychiatric illness. The particular focus of this work addresses sexual dysfunctioning
associated with depression and in response to antidepressant drug treatments, which occur at
rates much higher than that in the general population.
Depression is associated with many symptoms that can have a negative effect on intimacy
and sexual relationships; i.e., persistent sadness, loss of interest in activities once pleasurable,
decreased energy, feelings of worthlessness, and irritability and social withdrawal. Treatment of
depression and remission of depressive symptoms can improve sexual functioning; however,
antidepressants and other medications may cause or worsen sexual functioning, which is referred
to as treatment-induced or treatment-emergent sexual dysfunction. In the literature, there is a
wide range reported in the level of sexual dysfunction associated with various antidepressants.
Medications with a predominantly serotonergic mechanism of action (MOA), such as the
Selective Serotonin Reuptake Inhibitors (SSRIs), are associated with higher rates of sexual
dysfunction compared to drugs that primarily exhibit a non-serotonergic MOA. For example,
1
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medications, such as buproprion, which primarily exhibit dopaminergic and noradrenergic
effects, are associated with little or no sexual dysfunction. Antidepressants not only differ in the
level of impact on sexual functioning, but there are also differences in other tolerability
parameters and in efficacy, which vary across individuals, thus making selection of medication
therapy multifaceted and to a great extent individualized.
Treatment-associated side-effects often affect medication compliance and may lead to
discontinuation of treatment. Lack of medication compliance is a significant issue as this can
interfere with the treatment of depression, often resulting in an incomplete response or lack of
remission of depressive symptoms. Depression is associated with significant reductions in
quality of life, impaired productivity, and reduced overall health, and according to the Centers
for Disease Control and Prevention is the 10th leading cause of death in the United States. In
addition, sexual dysfunction is a commonly reported side-effect that often results in medication
discontinuation.
Assessment of sexual dysfunction in the past has predominantly relied on the patient
spontaneously reporting problems with sexual functioning to their physician or other medical
professional. Due to the sensitive nature of the topic, patient reporting is typically low and does
not reflect the actual prevalence of sexual dysfunction. Several prospective questionnaires have
been developed in order to more accurately assess the true levels of dysfunction associated with
medication treatment or illnesses. Most of the antidepressant-associated sexual dysfunction data
reported in the literature are from individual studies and include active treatment versus placebo,
treatment versus active comparator, or both. Comparing across studies to judge the comparative
level of sexual dysfunction is difficult due to natural variation across studies, and the use of
different assessment tools. A few meta-analyses and other systematic reviews have been
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conducted to address the issue of comparisons across antidepressants; however, the body of
research has grown, the methods for assessing sexual dysfunction have become more systematic,
and new, differentiated antidepressants have entered the market. Therefore, a current metaanalysis would provide useful information in the understanding of antidepressant associated
sexual dysfunction.
The purpose of this research is to assess the rate and level of antidepressant treatmentassociated sexual dysfunction as assessed by validated questionnaire in published and
unpublished data. The inclusion of unpublished data from Clinicaltrials.gov, pharmaceutical
websites, The Food and Drug Administration (FDA) summary basis of approval documents and
other sources will add further insight into the effects of antidepressants on sexual functioning.
The objectives of this analysis are to assess the rates of sexual dysfunction and to assess the level
of sexual dysfunction associated with commonly prescribed antidepressants and placebo.
The outcome of this research adds to the body of knowledge available on treatmentassociated sexual dysfunction. In the typical clinical setting, it is relatively uncommon for
clinicians to proactively question depressed patients regarding their sexual functioning. It is
equally unlikely that patients will bring up this topic with their healthcare provider. Usually, the
most urgent treatment goals are addressed initially (depressed mood, feelings of hopelessness,
worthlessness and any potential suicidal ideation of behaviors) and residual symptoms are often
considered as something to tolerate or perhaps deal with later. Unfortunately, the residual
symptoms of sexual dysfunction are often left unaddressed and can eventually lead to poor
overall treatment outcomes, lack of treatment compliance, remission and recurrence. Both
patients as well as healthcare providers are often hesitant to switch medications if the majority of
the depressed symptoms appear to be controlled. In part, the reluctance to address sexual
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dysfunction is due to the lack of effective and tolerable alternatives for an individual patient, as
well as lack of knowledge of the relative sexual dysfunction associated with available
antidepressants.
This research will provide a means for healthcare providers to reference the rates of sexual
dysfunction, including the recently approved antidepressants, among the second-generation
antidepressants. Having these data available as a meta-analysis provides a systematic,
standardized and comparative assessment, which is difficult to perform when reviewing
individual studies.

CHAPTER TWO
INTRODUCTION
The normal human sexual response cycle is generally described as having four phases: (1) Desire
or libido, characterized by an interest in sexual activity, (2) Excitement or arousal, the subjective
sense of sexual pleasure accompanied by physiological changes (including penile erection in
men, and vaginal lubrication and clitoral engorgement in women), (3) Orgasm, the peaking of
sexual pleasure and release of tension, and (4) Resolution, the sense of muscular relaxation and
general well-being (Masters & Johnson, 1966; Kaplan, 1979; Levin, 2008). Sexual dysfunction is
characterized by a disruption in the normal sexual response cycle and typically affects the desire,
arousal, and/or orgasm phase(s) (DSM-IV, 1994). Sexual dysfunction is prevalent and occurs in
approximately one-third of the general population. Some estimates report that as many as 43% of
women and 31% of men experience some degree of sexual dysfunction (Laumann et al., 1999).
Most studies have shown that a greater percentage of women than men report issues with sexual
functioning (Montgomery et al., 2002). In both sexes, the most common complaint is decreased
libido. In men, erectile dysfunction and premature ejaculation are common complaints; in
women, failure to achieve orgasm is often reported. There are several factors that contribute to
problems in normal sexual functioning, including medical illnesses (e.g., obesity, diabetes,
cardiovascular disease, sexually transmitted diseases, urinary tract infection, etc.), alcohol
consumption, substance abuse, social status, sexual trauma, medications, emotional issues and
psychiatric illness (e.g., depression or anxiety) (Laumann et al., 1999; Baldwin, 2001; Zajecka,
2001).
5
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Sexual dysfunction is a frequently reported symptom of depression and comparative studies
consistently report higher rates of sexual dysfunction in depressed patients compared to the
general population. Some studies have reported loss of sexual interest in approximately 70% of
depressed patients (Casper et al., 1985). A more recent prospective study (Zurich Cohort Study)
of 591 males and females from the general population of Zurich reported the prevalence of
sexual dysfunction in depressed patients as 50% versus 24% in non-depressed patients (Angst,
1998). Prior studies had reported on the association of sexual dysfunction and depression, but
had not systematically studied this association in untreated patients. Kennedy et al. (1999)
conducted a study of 134 men and women with depression who were willing to complete a
sexual functioning questionnaire before initiating antidepressant treatment. The results of this
study also indicated high levels of sexual dysfunction in patients who were currently
experiencing a major depressive episode. Approximately 50% of the women and 25% of the men
reported no sexual activity during the preceding month and 50% of women and 42% of men
reported a decrease in sexual desire. The most commonly reported issues with arousal in sexually
active patients were inability to sustain erection in men (46%) and less sexual arousal in women
(50%).
A 2013 review and meta-analysis conducted to assess the bidirectional relationship of
depression and sexual dysfunction, evaluated six studies on the risk of depression in patients
with sexual dysfunction, and six studies on the risk of sexual dysfunction in patients with
depression (Atlantis et al., 2012). The results of this review demonstrated that depressed patients
had a 50% to 70% increased risk of developing sexual dysfunction and those with sexual
dysfunction had a 130% to 210% increased risk of developing depression, reinforcing other data
demonstrating the inter-relatedness of sexual dysfunction and depression.
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Pathophysiology of Depression and Sexual Functioning
Depression is characterized by persistent sadness, loss of interest in activities once pleasurable
(including sex), decreased energy, feelings of worthlessness, irritability and social withdrawal;
symptoms which may adversely affect intimate relationships and create difficulties in sexual
relationships (Baldwin, 2001). The three main monoamine systems involved in the
pathophysiology of depression are serotonin (5-hydroxytryptamine, 5-HT), noradrenaline (NE),
and dopamine (DA). Postmortem, cerebrospinal fluid (CSF) and positron emission tomography
(PET) imaging studies in depressed unmedicated individuals have demonstrated decreased 5-HT,
NE and DA availability in the central nervous system (Nemeroff, 2008).
Most antidepressants function by increasing availability of serotonin in the brain; many also
increase the availability of noradrenaline and/or dopamine. Newer antidepressants (often referred
to as second generation), such as the selective serotonin reuptake inhibitors (SSRIs), have many
improvements over older antidepressants (e.g., tricyclics), particularly in safety; however,
response to SSRIs has been incomplete for many patients. This has led to further development of
antidepressants targeting the NE and/or DA systems (e.g., serotonin norepinephrine reuptake
inhibitors [SNRIs] or ‘atypical’ antidepressants such as buproprion, nefazodone, mirtazapine,
vilazodone, and vortioxetine).
Sexual function is regulated by complex interactions between the endocrine and nervous
systems. Among the hormones that may impact sexual function, testosterone, estrogen, and
oxytocin appear to have greater roles in facilitation of the desire, arousal and/or orgasm phases of
sexual response (Meston & Frohlich, 2000; Anil Kumar et al., 2009; Clayton & Montejo, 2006).
Neurotransmitters also appear to have a significant impact on sexual functioning. Data indicate
that there is a positive association between DA levels and desire and motivation for sexual
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activity; and in men, DA may be linked to penile erection. In men, NE levels positively correlate
with arousal and erection during masturbation and sexual activity. Some data have shown that
levels of NE increased up to 12-fold at orgasm and returned to baseline within 2 minutes of
orgasm. In women, blood plasma levels of NE increased during masturbation, peaked at orgasm
and declined after orgasm (Exton et al., 1999). The basis for targeting the DA system to improve
efficacy over SSRIs lies in the fact that the inability to experience pleasure is a significant
symptom of depression; and pleasure, regardless of the activity (including sexual behavior), is
primarily mediated by DA neurons and related neuronal circuits (Nemeroff, 2008).
Antidepressant Treatment-Associated Sexual Dysfunction
Treatment of depression and remission of depressive symptoms can improve sexual functioning;
however, antidepressants and other medications may cause or worsen sexual functioning, which
is referred to as treatment-induced or treatment-emergent sexual dysfunction. Because sexual
dysfunction is associated with comorbid conditions, including depression as well as medication
treatment, and in many cases the cause-effect relationship cannot be determined, the term
treatment-associated sexual dysfunction (TASD) is often used to describe this phenomenon. In
the Zurich Cohort Study (Angst, 1998), a comparison was performed between depressed patients
who received only psychotherapy or treatment with medication (50% received benzodiazepines
and 50% received antidepressants) versus those who received no treatment. Approximately 62%
of depressed patients who received medication experienced sexual problems as compared to 45%
of untreated depressed patients. Interestingly, the group of depressed patients who received
psychotherapy alone experienced an equally high rate (63%) of sexual dysfunction.
One meta-analysis of several antidepressants reported between 25% and 80% of people
taking antidepressants experience sexual dysfunction, depending on the medication they were
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taking (Serretti & Chiesa, 2009). In this analysis, the rate of sexual dysfunction in patients on
placebo was 14%, which is lower than the rate of sexual dysfunction in depressed patients
reported elsewhere in the literature indicating that the assessment of rates of sexual dysfunction
varies widely across studies.
Problems with sexual functioning can begin as early as 7 days after treatment with
medication, depending on the antidepressant, and improvement can also occur shortly after
discontinuation of treatment (Anita Clayton MD, personal communication). Ideally, this would
make the assessment of causality of sexual dysfunction and antidepressant treatment more
straight-forward given confounding factors are limited.
The understanding of sexual functioning has increased since the introduction of newer
antidepressants. Older generation antidepressants were associated with sexual dysfunction, but
were not selective in their effects on neurotransmitters (e.g., MAOIs). As SSRIs are selective in
that they specifically increase serotonin activity, the relationship between serotonin and sexual
response has been further clarified. Medications with a predominantly serotonergic mechanism
of action, e.g., the SSRI paroxetine, may be associated with the highest incidence of TASD
(~70%) compared to drugs that primarily exhibit a non-serotonergic MOA (Kennedy & Rizvi,
2009). Specifically, increased serotonin activity is associated with decreased libido and impaired
ejaculation (Meston & Frohlich, 2000). Often the symptoms of sexual dysfunction are mitigated
by a reduction in dose of the antidepressant. Furthermore, some SSRIs have been shown to be
useful in the treatment of premature ejaculation by increasing the latency to orgasm (Waldinger
et al., 1998).
As discussed above, the level of DA and NE affects the desire, arousal and orgasm phases of
the sexual response cycle. Antidepressants that primarily exhibit a non-serotonergic MOA be
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associated with fewer sexual side-effects than SSRIs. Some studies show that antidepressants
that have noradrenergic and well as serotonergic effects (SNRIs such as duloxetine, mirtazapine,
and venlafaxine) are associated with less sexual dysfunction, suggesting that increased
noradrenaline may mitigate the deleterious effect of serotonin on sexual dysfunction (Kennedy &
Rizvi, 2009). In one study, TASD was significantly lower with the SNRI duloxetine as compared
to the SSRI paroxetine (46% versus 61%); however, both were significantly worse than placebo
(Delgado et al., 2005). Medications that exhibit dopaminergic as well as noradrenergic actions
(e.g., buproprion) have been associated with little or no sexual side-effects, and are often used as
add-on therapies to counteract antidepressant-induced sexual dysfunction (Kennedy & Rizvi,
2009). In another study of TASD in patients taking one of several SSRIs or buproprion, rates of
sexual dysfunction ranged from 30% for citalopram and venlafaxine to 7% for buproprion
(Clayton et al., 2002).
A recently updated review from The Cochrane Collaboration (Taylor et al., 2013) evaluated
the effectiveness of various management strategies for sexual dysfunction associated with
antidepressants. Twenty-three studies that met the selection criteria were included in the metaanalysis. The strategies evaluated in these studies included the addition of further medication (22
studies) and change in antidepressant medication (one study). Based on this review, most
augmentation studies failed to show significant improvements in sexual dysfunction compared to
placebo; however, the addition of buproprion improved sexual functioning in men and women,
and the addition of sildenafil (Viagra) indicated greater improvement in erectile function over
placebo in men.
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Impact of TASD on the Treatment of Depression
Treatment-associated side-effects often affect medication compliance and may lead to
discontinuation of treatment. One study surveyed 350 depressed patients regarding compliance
with antidepressant treatment and reasons for noncompliance and/or discontinuation (Ashton et
al., 2005). Of the 350 patients surveyed, 60% had completely discontinued treatment with the
most common reasons being lack of efficacy (44%), “didn’t like the way the medicine made me
feel” (37%), “lost interest in sex” (23%), “tiredness” (18%) and “weight gain” (16%). Of those
currently prescribed an antidepressant (97%), 22% indicated they were noncompliant, with
“couldn’t have an orgasm” (20%) and “lost interest in sex” (20%) reported as reasons for
noncompliance by those patients. In addition, “lost interest in sex” was reported by 47% of all
patients prescribed an antidepressant with “unable to have erection” and “difficulty reaching
orgasm” considered to be “extremely difficult to live with” by 25% and 24% of the patients,
respectively. Although there are not many studies assessing patient self-reported reasons for
noncompliance, sexual dysfunction is a commonly reported side-effect associated with treatment
and does lead to medication discontinuation and often switching antidepressants to find one that
produces less sexual dysfunction.
Lack of medication compliance is a significant issue as this can interfere with the treatment
of depression, leading to lack of, or incomplete response or remission of depressive symptoms.
Depression is associated with significant reductions in quality of life, impaired productivity,
reduced overall health, and substantial economic burden (World Health Organization, 2012;
Bech et al., 2006). Depression is also associated with an increased risk of suicide (Reeves &
Ladner, 2010; Stone et al., 2009; Barbui et al., 2009). According to The World Health
Organization (WHO), major depression is a leading cause of disease burden in North America
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and the fourth leading cause worldwide as of year 2000. By year 2020, WHO estimates that
depression will be the second leading cause of global burden of disease. In the United States,
major depressive disorder (MDD) affects 5-7% of people each year, and 13-16% of individuals
during their lifetime (Hasin et al., 2005; Kessler et al., 2003; Kessler, Berglund et al., 2005;
Kessler, Chui et al., 2005); therefore, lack of treatment compliance due to side-effects, in
general, and TASD, specifically, can have significant impact on those suffering from depression.
Assessment of Sexual Functioning
Initially, assessment of sexual dysfunction relied on the patient spontaneously reporting sexual
functioning-related adverse events. Patient reporting is typically low and does not reflect the
actual prevalence of sexual dysfunction. In one study of 344 patients using SSRIs, spontaneously
reported sexual dysfunction was 14.2% compared to 58.1% when reported via questionnaire
(Montejo-Gonzalez et al., 1997). As a result of the propensity to under-report sexual side-effects,
prospective questionnaires were designed in order to obtain a more accurate assessment of sexual
dysfunction. Several questionnaires have been developed to assess sexual dysfunction in
patients; some are administered via interview (e.g., Psychotropic-Related Sexual Dysfunction
Questionnaire [PRSexDQ]), self-reported or by interview (e.g., Arizona Sexual Experiences
Scale [ASEX], Changes in Sexual Functioning Questionnaire [CSFQ], Rush Sexual Inventory
Scale, and Sex Effects Scale), and are usually available in male and female versions. Most record
sexual functioning using categories on a Likert scale, but some assess sexual functioning using
anchors on a visual analog scale (VAS). Criteria are often identified that categorize the patient as
having normal or abnormal sexual dysfunction and many have subscales that assess the three
main phases of the sexual response cycle: desire, arousal, and orgasm.
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In one study of 1022 patients that utilized a prospective questionnaire (PRSexDQ) conducted
by the Spanish Working Group of Psychotropic-related Sexual Dysfunction, sexual dysfunction
associated with antidepressants as a whole was 62.4% for men and 56.9% for women, although
women reported greater severity of sexual dysfunction (Montejo, et al., 2001). A meta-analysis
of studies exploring antidepressant-related sexual dysfunction was conducted by Serretti and
Chiesa (2009). This analysis examined the overall rate of treatment-emergent sexual dysfunction
as well as the rates of dysfunction in the sexual response phases of desire, arousal, and orgasm.
The authors targeted studies examining antidepressant-related sexual dysfunction in patients
without prior sexual dysfunction, and the method of acquiring data was through direct inquiry or
patient completed questionnaires. In addition to direct inquiry, various scales were included, but
the most common were the ASEX and CSFQ. The literature review for this analysis was
performed on published studies through July 2008 using MEDLINE. While this study included
useful data on many of the commonly prescribed antidepressants, as the authors note the research
is subject to publication bias. In addition, the field of study in TASD has increased over the last
several years and more articles have been published on newer antidepressants.
A more recent meta-analysis by Reichenpfader et al. (2014) evaluated the comparative harms
of second-generation antidepressants in depressed patients utilizing network analysis. The
authors concluded that the comparative risk of sexual dysfunction associated with specific
antidepressants could not be precisely determined due in part to the variation of sexual
dysfunction adverse events reported across studies for a given antidepressant. The variation seen
across studies could have been impacted by the inclusion of data gathered by various methods,
including spontaneously reported adverse events. Therefore, a review that includes only sexual
dysfunction data from prospective questionnaires may reduce the variation in reporting and
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provide a greater distinction in the relative incidence of sexual dysfunction associated with
antidepressant treatment.
The purpose of this research is to assess the rate and level of treatment-associated sexual
dysfunction as assessed by questionnaire in published and unpublished data (i.e.,
clinicaltrials.gov, pharmaceutical company websites and The Food and Drug Administration
(FDA) summary basis of approval documents were reviewed). Data from these sources are
publicly available, but many of the studies are not published in journals. Including these data will
add further insight into the effects of antidepressants on sexual functioning.
Objectives
The objectives of this research are to assess the rates, and the level of sexual dysfunction
associated with commonly prescribed antidepressants versus placebo.

CHAPTER THREE
METHODS
This research is a systematic review and meta-analysis of the rates of treatment-associated sexual
dysfunction in depressed patients taking commonly prescribed antidepressants approved in the
United States. This analysis evaluated the level of sexual dysfunction in the intent-to-treat
population (i.e., all the patients who were enrolled and randomly allocated to treatment in
randomized clinical trials, and are included in the analysis and analyzed in the groups to which
they were randomized) as well as by sex when data were available.
Data Sources and Search Criteria
The literature search was performed using Ovid® (searching MEDLINE and EMBASE
databases), and clinicaltrials.gov. The initial database search included articles published through
March 2016. The following terms were used to search titles and abstracts for the following
associations using Ovid®: “depression OR MDD”; “antidepressant OR antidepressive agents”;
“randomized AND double-blind”; and “sexual dysfunction OR sexual function OR libido.” Each
search result linked to include all associations. Clinicaltrials.gov was searched using the
following terms: “depression AND antidepressant AND randomized AND sexual.” Only
interventional studies and studies with results were included. The Food and Drug Administration
(FDA) summary basis of approval documents were reviewed for sexual functioning data via
validated questionnaires for the following commonly prescribed antidepressants: duloxetine,
venlafaxine, desvenlafaxine, buproprion, escitalopram, sertraline, fluoxetine, vilazodone, and
vortioxetine.
15
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Study Selection
Typical Study Characteristics
The typical studies that met the criteria below were randomized, double-blind, placebocontrolled studies of the efficacy or tolerability of at least one approved antidepressant. Many of
the studies also included an active-control (an approved antidepressant) in addition to the test
antidepressant. The patient population was acute major depressive disorder (MDD) patients who
were experiencing a major depressive episode. Eligible studies included a proactive
questionnaire assessing patient sexual functioning at baseline prior to study interventional
treatment, and at least one timepoint post-treatment. Based on the criteria of the questionnaire,
patients were categorized as having normal or abnormal sexual functioning prior to treatment
and at one or more post-baseline timepoints. Most studies included a change from baseline total
score on the sexual functioning scale. Studies were placebo-controlled to allow comparison of
active treatment to no treatment. The primary objective of most studies was efficacy of the
antidepressant on depressive symptoms, with sexual functioning being assessed as a tolerability
endpoint.
Study Selection Process and Criteria
Two trained reviewers (including the author) independently screened the abstracts and full
texts articles for eligibility of studies identified by the initial search criteria. The screening
process included two steps: an initial review of the titles and abstracts followed by a review of
the full text of studies that meet the initial screening criteria. A third party reviewed any
disagreements and resolved.
The following selection criteria were applied.
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Studies were included based on the following criteria:
1. Study was randomized, double-blind, placebo-controlled antidepressant interventional
study.
2. Study included human patients at least 18 years of age who are being treated for
depression.
3. Study included only monotherapy antidepressant interventions (i.e., studies examining
combination therapies were excluded to minimize confounding factors).
4. Study assessed sexual dysfunction/functioning through the use of a validated sexual
functioning questionnaire.
5. Study evaluated only antidepressants approved by FDA for the treatment of depression.
6. Sexual functioning was assessed at screening/baseline and at least one post-baseline
assessment during antidepressant treatment.
7. Study evaluated the safety/tolerability and/or efficacy of an antidepressant.
8. Study evaluated antidepressant doses within the approved efficacious dose range;
however, the study could have been positive, negative or failed in terms of efficacy in the
treatment of depression.
9. Treatment period of study was at least 6 weeks duration.
10. Publication was in English.
Studies were excluded based on the following criteria:
1. Study identified antidepressant intervention by drug class, but not antidepressant name.
2. Study evaluated patients with sexual dysfunction not related to antidepressants or
depression, e.g., study evaluated a comorbid condition associated with sexual
dysfunction.
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3. Study included patients who had conditions, or were taking medications known to affect
sexual functioning, other than depression and antidepressants.
4. Study was reported only in abstract form.
Studies for which both reviewers agreed did not meet selection criteria were excluded.
Quality Assessment
The risk of bias was assessed by two independent reviewers (including the author) utilizing the
criteria developed by the Cochrane Collaboration (Higgins et al., 2011). An assignment of “low”,
“unclear” or “high” risk of bias was applied to the following domains: Sequence generation,
allocation concealment, blinding of participants, personnel and outcome assessors, incomplete
outcome data, selective outcome reporting, and other sources of bias (see Table 1). Any
disagreements on assessments were resolved between the reviewers by consensus.
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Table 1. Cochrane Collaboration’s tool for assessing risk of bias
Type of bias

Description

Selection bias

Systematic differences between
baseline characteristics of the
groups that are compared
Systematic differences between
groups in the care that is
provided, or in exposure to
factors other than the
interventions of interest
Systematic differences between
groups in withdrawals from a
study
Systematic differences between
groups in how outcomes are
determined

Performance bias

Attrition bias
Detection bias

Reporting bias
Other bias

Systematic differences between
reported and unreported findings
Any important concerns not
covered in the other domains of
the tool

Relevant domains in the
Collaboration’s ‘Risk of bias’
tool
• Sequence generation
• Allocation concealment
• Blinding of participants,
personnel and outcome assessors
• Other potential threats to
validity
•Incomplete outcome data
• Blinding of participants,
personnel and outcome assessors
•Blinding of participants,
personnel and outcome assessors
• Other potential threats to
validity
•Selective outcome reporting
•Bias due to problems not
covered elsewhere

The following data were extracted from the sources: (a) study population and demographic
information, (b) participant eligibility criteria, (c) study design, duration and sample size, (d)
method of randomization, (e) method of maintenance of blind, (f) intervention and dose, (g)
patient disposition (completion, withdrawals, and reason for withdrawal), (h) sexual functioning
assessment tool, (i) incidence of sexual dysfunction, (j) sexual functioning assessment tool mean
total score, where available, (k) percent patients who have shifted from normal to abnormal
sexual functioning, where available, and (l) antidepressant treatment effect. Further details are
outlined in the coding manual found in Appendix A.

20
The author coded the data for all the studies and an independent trained coder coded a 20%
sample of the studies meeting criteria. Any discrepancies were discussed and resolved between
the author and independent coder.
Outcome Measures
Primary Outcomes
The primary outcome is the standardized mean effect for sexual dysfunction for each
antidepressant versus placebo as assessed by validated sexual functioning questionnaires.
Secondary Outcomes
The following secondary outcomes were examined:
1. Odds ratio for developing sexual dysfunction of each antidepressant versus placebo as
assessed by validated sexual functioning questionnaires.
2. Assessment of differences by gender, and by phases of the sexual response cycle, where
data were available.
Sexual Dysfunction Assessment Tools
In clinical research trials, the most frequently used scales for assessing sexual functioning
associated with antidepressant use are the Arizona Sexual Experiences Scale (ASEX) and
Changes in Sexual Functioning Questionnaire (CSFQ); however, several other scales have been
utilized to a lesser extent and reported in the literature. The ASEX and CSFQ scales are
summarized below, and examples of each of the scales described below are listed in Appendix B.
Arizona Sexual Experiences Scale (ASEX)
The ASEX is a brief self-report or clinician-administered scale with items assessing five core
domains of sexual functioning: drive, arousal, penile erection/vaginal lubrication, ability to
achieve orgasm and satisfaction from orgasm (McGahuey et al., 2000). Each of the five
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questions are rated on a 6-point Likert scale ranging from hyperfunction (1) to hypofunction (6)
with a total score range of 5-30. Higher scores indicate worse sexual functioning. The third
question differs in the male and female version and relates to penile erection or vaginal
lubrication. The ASEX was designed to be simple and easy to use, and to assess sexual activity
regardless of the availability of a sexual partner. An ASEX score of ≥19, or any 1-item score ≥5,
or any 3-item scores ≥4 indicates a high probability of sexual dysfunction. The reliability and
validity of the ASEX was examined in 38 healthy control and 58 psychiatric patients aged 18
years and older. The Cronbach’s alpha coefficient for the ASEX was .9055. The test–retest
reliability for the ASEX was also calculated (for patients, r = .801, p < .01, for controls, r = .892,
p < .01). The validity of the ASEX was tested against another validated questionnaire that
included assessment of sexual functioning. Further details on the reliability and validity of the
ASEX can be found in McGahuey et al., 2000. Sexual functioning data from the ASEX are
typically reported as rates of normal/abnormal sexual functioning and rates of patients
developing sexual dysfunction post-treatment. Total score changes over time are also reported;
however, this is only possible when all five questions are answered.
Changes in Sexual Functioning Questionnaire (CSFQ)
The CSFQ is a self-report or clinician-administered scale that contains 36 items (men) and 35
items (women), which assesses five domains of sexual functioning (sexual desire/frequency,
sexual desire/interest, pleasure, arousal, and orgasm), and three phases of the sexual response
cycle (desire, arousal and orgasm) (Clayton et al., 1997). The first 21 items apply to both men
and women. Items are rated on a 5-point Likert scale where a higher score reflects better sexual
functioning. The CSFQ was designed to differentiate between people who have had life-long
poor sexual functioning and those who have developed sexual dysfunction after normal
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functioning. A shorter 14-item version of this scale, the CSFQ-14, was developed to more
efficiently assess the domains of sexual functioning evaluated by the longer version and has
demonstrated good construct validity and internal reliability. The reliability and validity of the
CSFQ-14 was examined in 6, 286 patients evaluated for depression. Cronbach’s alpha coefficient
was calculated for the whole sample and for each sex separately. Cronbach’s alpha for the total
CSFQ-14 score was .90 for the female version and .89 for the male version. Further details of the
reliability and of the validity can be found in Keller et al., 2006.
A score of less than 47 for men and less than 41 for women indicates sexual dysfunction on
the CSFQ-14 scale (Keller et al., 2006). The CSFQ-14 is more commonly used that the longer
version, and has been the choice for use in clinical trials and other studies reported in the
literature. Sexual functioning data per the CSFQ-14 are reported as rates of normal/abnormal
sexual functioning, the rate of patients developing sexual dysfunction post-treatment, and total
scores or scale subscores changes.
The methods of sexual functioning assessment have varied widely, including by patient
interview, reporting of adverse events, and various questionnaires. This varying format of
inquiry makes determination of the impact of a given antidepressant on sexual functioning
difficult to assess across studies. For example, reports of adverse events only are known to be
under-reported and unreliable, and are therefore not helpful in differentiation effects compared to
placebo. Structured questionnaires that assess the same construct, i.e., domains related to the
sexual response cycle, yield more informative data. For example, the ASEX, CSFQ, and
Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) assess aspects of desire,
arousal and orgasm (phases of the sexual response cycle). These scales, which have also been
validated, can be used to calculate scores that indicate the level of impaired sexual functioning.
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In addition, the ability to calculate abnormal and normal sexual functioning from scale scores
provides a more reliable assessment of odds ratios compared to calculations using adverse event
reporting.
Data Analysis
The data were analyzed using SPSS (version 25) and specialized meta-analysis macros written
specifically for this program (Lipsey & Wilson, 2001).
Effect Size Metrics
Odds ratios (ORs) were used as the effect size metric for binary outcomes and standardized
mean difference effect sizes were used as the effect size metric for continuous outcomes for each
antidepressant. Effect sizes were coded such that the larger effect size represents positive
outcomes (i.e., better sexual functioning compared to placebo).
Odds ratios were calculated for overall rates of sexual dysfunction (percent of patients with
abnormal sexual dysfunction after antidepressant treatment). The logged odds-ratio was
calculated as follows:
ܵܧைோ = ln(OR)

ܽ݀
ܾܿ

Where ln(OR) is the natural log of the odds ratio, a and b are the frequencies of normal and
abnormal sexual functioning in the treatment group, and c and d are the respective frequencies in
the comparison (placebo) group.
The sampling variance of the logarithm of the odds ratios was calculated as follows:
ܸܽݎ୪୬(ைோ) =

1 1 1 1
+ + +
ܽ ܾ ܿ ݀
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The standardized mean difference effect for each antidepressant were used as the effect size
metric for sexual functioning scale scores after treatment. Mean effect sizes were calculated
following the independent groups pretest-posttest design in which two groups of participants are
assigned to alternate treatment conditions (e.g., experimental and control) (Becker, 1988; Morris
& DeShon, 2002; Morris, 2008). The majority of the studies reported mean change or gain scores
(i.e., the difference between pretest and posttest sexual functioning scores) and standard
deviations of the change for each treatment group; therefore, standardized effect sizes for each
comparison (antidepressant versus control) within study were calculated using mean change
scores and standard deviations of the change. None of the studies reported the population
correlation between pretest and posttest scores, so the correlation was assumed to be 0.8.
Standardized effect sizes were calculated using an online calculator companion to Practical
Meta-Analysis by Mark W. Lipsey and David B. Wilson, 2001, which can be accessed at the
following web address: http://www.campbellcollaboration.org/escalc/html/EffectSizeCalculatorHome.php. Formulas for the effect size calculations can be found in Morris and DeShon (2002).
Because the standardized effect size can be upwardly biased in small samples, the standardized
effect size was adjusted using the following Hedges correction (Hedges, 1981):
3
ඐ ܵܧ
4ܰ − 9
Where N is the total sample size and  ܵܧis the unadjusted effect size.
ܵܧ௦ = ඌ1 −

All effect sizes were reported using a 95% confidence interval.
In studies that included treatment groups with more than one effective dose of a particular
antidepressant, effect sizes were calculated within study by dose and pooled to create the mean
effect size for that antidepressant, as there were insufficient studies to calculate effect sizes by
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dose. Some studies compared different antidepressants (e.g., duloxetine and paroxetine versus
placebo) to the same placebo arm; therefore, some effect sizes utilized multiple comparisons to
placebo. This was also true for antidepressants of different doses in the same study.
Missing Data
Data from the intent-to-treat analyses were used. When analysis from intent-to-treat (ITT)
population was not available, the analysis from patients who completed study were used. When
information needed to complete the primary measures was missing, additional information was
gathered by contacting the authors, via the clinicaltrials.gov or via pharmaceutical company
websites. Review of FDA summary basis of approvals did not reveal any additional data.
Descriptive Statistics
Descriptive statistics were used to summarize the current state of the literature and highlight
gaps in research on sexual dysfunction associated with antidepressant treatment. Descriptives
were synthesized across primary studies on the characteristics of methodology, participants, type
of intervention, assessment scale(s) used and outcome.
Sensitivity Analysis
The data were evaluated for outliers. The effect size distributions were evaluated for outliers
using Tukey’s (1977) inner fence criterion. The distribution of sample sizes as well as weights
(for odds-ratios) were examined for any extreme values. Publication bias was evaluated using
funnel plots. Underrepresentation of unpublished studies, which are more likely to have
unfavorable results, can substantially bias effect size estimates (Borenstein et al., 2009). All
reasonable attempts were made to include unpublished research such as accessing
clinicaltrials.gov, and pharmaceutical websites and FDA summary basis of approval documents.
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Synthesis of Effect Sizes and Assessment of Heterogeneity
The distribution of effect sizes across all antidepressants was examined descriptively using
forest plots. Random effects models were planned to account for heterogeneity between studies
given the likely variation in study characteristics and for the importance of supporting
generalization of findings beyond the included studies (Borenstein et al., 2009). Random effects
weighed mean effect sizes and 95% confidence intervals for each study were calculated if
sufficient comparisons existed. The random effects variance component was calculated using the
DerSimonian/Laird estimate (DerSimonian & Laird, 1986). Using random effects models allows
for the accounting for within study sampling variance and between study variability; however, if
the number of studies is small it is not possible to obtain a good estimate of the random effects
variance. Because mean effect sizes were calculated for each antidepressant, there were too few
comparisons to estimate the random effects variance for each antidepressant; therefore, the data
calculated using the fixed effects model is presented.
Assessment of heterogeneity of the effect size differences between studies was evaluated
using both the χ2 and I2 statistics. Tests of heterogeneity are a measure of the variability in the
distribution of effect sizes, and in a homogeneous distribution, the amount of variability is no
greater than that which is expected due to sampling error alone. The null hypothesis of
homogeneity was rejected in the case of a χ2 value with p<0.05. For interpretation of the I2
statistic, the guidance suggested in The Cochrane Handbook was used for substantial to
considerable heterogeneity (i.e., I2 more than 50%). Discussion is included for heterogeneity in
results found.
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Moderator Analyses
A number of moderator analyses were planned if there were sufficient studies eligible.
Significant variability in effects (i.e., the Q statistic indicates significant heterogeneity in effect
sizes) was expected. It is known that many antidepressants have negative effects on sexual
functioning, and antidepressants may differ in these effects. Thus, separate meta-analyses were
conducted for each antidepressant. In addition, the effects of antidepressants often differ by
gender and potentially by type of sexual functioning scale.
Moderator analyses were planned for gender and sexual functioning scale; however, only
gender differences were examined since there was insufficient number of studies and data to
examine differences by sexual functioning scale, or any other study characteristic. Gender
differences are discussed in the Results section.

CHAPTER FOUR
RESULTS
Literature Search, Identification and Selection
Figure 1 shows a flow diagram summary of the search and selection of all data sources evaluated
for this meta-analysis. In the initial search, 320 reports were identified, with 240 being identified
through searching within the electronic database, Ovid. Ovid allows for removal of duplicates
during the search; therefore, the 240 sources reflect removal of duplicates. An additional 80
reports were identified through other means, such as, Clinicaltrials.gov, citation searches,
pharmaceutical websites with study results posted, and the FDA summary basis of approval
documents. Abstracts (or titles when abstracts were not available) were screened for initial
relevance. Of the 320 screened, 222 were excluded that were clearly not eligible for inclusion.
Full text copies were obtained or retrieved for the remaining 98 reports and further reviewed for
inclusion. Of these, 79 were deemed not eligible with the primary reasons being irrelevant or
simply wrong study design, and no sexual functioning questionnaire used. Details of the reasons
for exclusion are provided in Figure 1. The remaining 19 reports were used for coding of the 17
eligible studies. During the coding process, an additional 3 sources of data were obtained in
order to complete the required data for calculation of effects sizes and odds ratios. Two of the
reports included pooled data on two or more studies. Data sources for the original study reports
were obtained if possible.
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Identification

Figure 1. Flow diagram, summary of search and selection
Records identified through
database searching:
duplicates removed
(n=240)

Additional records
identified through other
sources
(n=80)

Eligibility

Screening

Records after duplicates removed
(n=320)

Records screened
(n=320)

Full-text data sources
assessed for eligibility
(n=98)

Included

Reports included in
qualitative synthesis
(n=19)

Reports included in
quantitative synthesis
(meta-analysis)
(n=19)

Records excluded
(n=222)

79 full-text data sources
excluded, with reasons
-Wrong study design (n=27)
-No sexual dysfunction scale
(n=20)
-Incomplete sexual
functioning data (n=14)
-Sexual functioning scaled
not validated (n=10)
-Wrong drug/dose/population
(n=6)
-No placebo arm (n=2)
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Characteristics of Included Studies
The details of the eligible studies are provided in Table 2. The 17 eligible studies included 9,475
men and women who were diagnosed with acute major depressive disorder (MDD). The total
patients included in the sample excluded Study 5, which was pooled data from studies 6 and 7,
but included pooled Study 10 and not studies 16-18. Study 10 included data from 4 of the Lilly
studies, but only 3 of the 4 Lilly studies referenced in study 10 were available as individual
reports. All but two studies had 8-week treatment periods, with the remaining two having a 10week and 12-week treatment period. All 17 studies were placebo-controlled as per inclusion
criteria to allow for consistent comparison of mean effect sizes; however, 13 of the studies also
included more than one antidepressant in addition to placebo allowing for multiple calculation of
effect sizes versus placebo within the same trial, potentially reducing inter-study variability.
However, multiple comparisons to placebo also introduces dependencies in effect sizes. As
mentioned, study duration was also consistent, with 15 of the 17 studies having an 8-week
treatment period. All of the eligible studies were randomized controlled trials funded by
pharmaceutical companies likely because the inclusion criteria required that the sexual
functioning scale utilized be validated, and pharmaceutical companies tend to prioritize the use
of validated scales, primarily for regulatory reasons. The randomization schemes for these
studies were centrally generated and treatment assignment was allocated in a double-blind
fashion with investigative sites utilizing either interactive voice response system or a web-based
system.
Only studies that utilized the ASEX and CSFQ-14 were included in the analysis as they
contained the necessary data to calculate mean effect sizes from total score and odd ratios from
determination of normal and abnormal sexual functioning. The Psychotropic-Related Sexual
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Dysfunction Questionnaire (PRSexDQ) has been predominantly used in schizophrenia
populations and results in depressed populations were published in Spanish; therefore, no studies
that utilized this scale met eligibility criteria. Six studies utilized the CSFQ-14 scale and 11 used
the ASEX scale.
Publication year ranged from 2004 through 2015 and reflected the fact that inclusion of
validated sexual functioning questionnaires in studies is fairly recent. Most (81%) of the studies
were conducted in the United States. The majority (64%) of participants were women and ranged
from 56% to 74%, which is consistent with the prevalence of women versus men with MDD in
the overall population. Participants were predominantly Caucasian (80%) and African American
(17%). The slightly higher percentage of Caucasians in the overall population reflects the
inclusion of studies with sites in Europe, which enrolled over 95% Caucasians. The mean age in
the overall population of studies combined was 42 years.

Table 2. Summary of study design and references.
Study
Antidepressant
Dose per arm Number of
identifier
(mg/QD)
Subjects
(ITT)
1.Clayton et Buproprion
300-450 mg
133
al., 2006 (a)
flexible
Escitalopram
10-20 mg
130
flexible
Placebo
NA
127
2.Clayton et Buproprion
300-450 mg
129
al., 2006 (a)
flexible
Escitalopram
10-20 mg
130
flexible
Placebo
NA
125
3.Clayton et Duloxetine
60 mg fixed
67M, 118F
al., 2007
Escitalopram
10 mg fixed
62M, 145F
Placebo
NA
37M, 59F
4.Clayton,
Reddy, et
al., 2013;
Dunlop, et
al., 2011

Desvenlafaxine
Placebo

50 mg fixed
NA

82M, 157F
37M, 74F

5.Clayton,
Kennedy, et
al., 2013 (b)

Vilazodone
Placebo

40 mg fixed
NA

159M, 241F
174M, 227F

Study Design Time of
endpoint
Rand, DB,
PBO and
active
controlled,
efficacy
Rand, DB,
PBO and
active
controlled,
efficacy
Rand, DB,
PBO and
active
controlled,
efficacy
Rand, DB,
PBO
controlled,
efficacy

Week 8

Sexual
Function
tool
CSFQ-14

Endpoints

Reported by
sex

Mean
change
from BL

Male/female
combined

Week 8

CSFQ-14

Mean
change
from BL

Male/female
combined

Week 8

CSFQ-14

Week 12

ASEX

Mean
change
from BL;
percent
SD
Mean at
endpoint;
percent
SD

Male/female
reported
separately;
combined
calculated
Male/female
reported
separately;
combined
calculated

Pooled SD
data from
studies 6 and
7

Week 8

ASEX,
CSFQ-14

Percent
SD

Male/female
reported
separately;
combined
calculated
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Study
identifier

Antidepressant

Dose per arm
(mg/QD)

Study Design Time of
endpoint

40 mg fixed
NA

Number of
Subjects
(ITT)
72M, 124F
72M, 124 F

Rand, DB,
PBO
controlled,
efficacy

Week 8

Sexual
Function
tool
ASEX

6.Clayton,
Kennedy, et
al., 2013
(b); Rickels
et al., 2009
7.Clayton,
Kennedy et
al., 2013
(b); Khan et
al., 2011
8.Clayton,
Tourian, et
al, 2015 (c)

Vilazodone
Placebo

9.Clayton,
Gommoll,
et al., 2015;
Mathews et
al., 2015
10.Nelson
et al., 2006
(d)

Vilazodone
Placebo

40 mg fixed
NA

87M, 119F
102M, 108F

Rand, DB,
PBO
controlled,
efficacy

Week 8

CSFQ-14

Mean
change
from BL

Desvenlafaxine
Desvenlafaxine
Placebo

50 mg fixed
100 mg fixed
NA

138M, 300F
149M, 307F
135M, 300F

Rand, DB,
PBO
controlled,
efficacy

Week 8

ASEX

Vilazodone
Vilazodone
Citalopram
Placebo

20 mg fixed
40 mg fixed
40 mg fixed
NA

201M, 267F
192M, 259F
205M, 257F
212M, 264F

Week 10

CSFQ-14

Duloxetine

736

Week 8

ASEX

Paroxetine

40-120 mg
fixed
20 mg fixed

Placebo

NA

371

Rand, DB,
PBO and
active
controlled,
efficacy
Pooled data
from 4 Rand,
DB, PBO,
and active
controlled,
efficacy;
including
studies 16-18

Mean
change
from BL,
percent
SD
Mean
change
from BL,
percent
SD
Percent
SD

359

Endpoints

Reported by
sex

Mean
change
from BL

Male/female
reported
separately;
combined
calculated
Male/female
reported
separately;
combined
calculated
Male/female
reported
separately
and
combined
Male/female
reported
separately
and
combined
Male/female
combined
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Study
identifier

Antidepressant

Dose per arm
(mg/QD)

11.Hewett
et al., 2010

Buproprion

Placebo
Vortioxetine
Vortioxetine
Duloxetine
Placebo

150-300 mg
flexible
75-150 mg
flexible
NA
15 mg fixed
20 mg fixed
60 mg fixed
NA

Vortioxetine
Vortioxetine
Duloxetine
Placebo

15 mg fixed
20 mg fixed
60 mg fixed
NA

31M, 81F
25M, 86F
28M, 85F
35M, 93F

Vortioxetine
Vortioxetine
Placebo

10 mg fixed
20 mg fixed
NA

30M, 93F
31M, 89F
41M, 96F

Vortioxetine
Vortioxetine
Placebo

10 mg fixed
15 mg fixed
NA

38M, 91F
33M, 88F
44M, 89F

Venlafaxine
12.Bouleng
er et al.,
2014;
Clinicaltrial
s.gov
NCT011409
06
13.Mahable
shwarkar,
Jacobsen,
Chen et al.,
2015 (e)
14.Jacobsen
et al., 2015
(e)
15.Mahable
shwarkar,
Jacobsen,
Serenko et
al., 2015 (e)

Number of
Subjects
(ITT)
193
202
186
147
148
144
156

Study Design Time of
endpoint
Rand, DB,
PBO and
active
controlled,
efficacy
Rand, DB,
PBO and
active
controlled,
efficacy

Week 8

Sexual
Function
tool
CSFQ-14

Endpoints

Reported by
sex

Mean
change
from BL

Male and
female
combined

Week 8

ASEX

Mean
change
from BL

Male/female
combined

Rand, DB,
PBO and
active
controlled,
efficacy
Rand, DB,
PBO
controlled,
efficacy

Week 8

ASEX

Week 8

ASEX

Rand, DB,
PBO
controlled,
efficacy

Week 8

ASEX

Mean
change
from BL,
percent
SD
Mean
change
from BL,
percent
SD
Mean
change
from BL,
percent
SD

Male/female
reported
separately
and
combined
Male/female
reported
separately
and
combined
Male/female
reported
separately
and
combined
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Study
identifier

Antidepressant

Dose per arm
(mg/QD)

Study Design Time of
endpoint

40 mg fixed
80 mg fixed
20 mg fixed
NA

Number of
Subjects
(ITT)
58
52
44
47

Rand, DB,
PBO and
active
controlled,
efficacy

Week 8

Sexual
Function
tool
ASEX

16.https://w
ww.lilly.co
m/clinicalstudyreport-csrsynopses
F1J-MCHMATa
17.https://w
ww.lilly.co
m/clinicalstudyreport-csrsynopses
F1J-MCHMATb
18.https://w
ww.lilly.co
m/clinicalstudyreport-csrsynopses
F1J-MCHMAYa

Duloxetine
Duloxetine
Paroxetine
Placebo

Endpoints

Reported by
sex

Mean
change
from BL,
percent
SD in
pooled
Study 10

Male/female
combined

Duloxetine
Duloxetine
Paroxetine
Placebo

40 mg fixed
80 mg fixed
20 mg fixed
NA

50
45
48
49

Rand, DB,
PBO and
active
controlled,
efficacy

Week 8

ASEX

Mean
change
from BL,
percent
SD in
pooled
Study 10

Male/female
combined

Duloxetine
Duloxetine
Paroxetine
Placebo

80 mg fixed
120 mg fixed
20 mg fixed
NA

19M, 40F
21M, 32F
17M, 39F
17M, 31F

Rand, DB,
PBO and
active
controlled,
efficacy

Week 8

ASEX

Mean
change
from BL,
percent
SD in
pooled
Study 10

Male/female
reported
separately
and
combined

ITT = Intent-to-treat; QD = once daily; Rand = randomized; DB = double-blind; PBO = placebo; CSFQ-14 = Changes in Sexual Functioning Questionnaire;
BL = Baseline; SD = sexual dysfunction; ASEX = Arizona Sexual Experiences Scale; M = male; F = female
(a) Two studies of identical design were reported in the same publication.
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(b) Clayton, Kennedy et al. (2013) report sexual functioning change scores for 2 separate studies and pooled data for percent patients with and without sexual
dysfunction at endpoint (identified as studies 5, 6, and 7 for clarity).
(c) Number of patients per group is different for ASEX total score change from baseline and for percent patients with and without sexual dysfunction. The
larger number is reported here.
(d) Nelson et al. (2006) reports percent patients with and without sexual dysfunction for 4 studies pooled, however, the sexual functioning change scores were
obtained from 3 of those studies from clinical trial synopses provided on the pharmaceutical companies website (studies 16, 17 and 18).
(e) Additional data was provided by one of the publication authors in order to calculate mean effect scores.
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Study Level Demographic Characteristics
Baseline demographic characteristics by study are listed in Table 3. Pooled studies 5 and 10
are not included as they are represented by individual studies as described in Table 2. Mean
Montgomery–Åsberg Depression Rating Scale (MADRS) total scores, where included, indicated
that the population enrolled was moderate to severely depressed (MADRS total score >30).
Three studies (16, 17 and 18) enrolled mildly depressed patients with mean MADRS total scores
of 22 and 23. Hamilton Depression Rating Scale (HAM-D) 17-item total scores were generally
consistent with MADRS total scores with regard to severity of depression in studies where both
were assessed. Mean baseline CSFQ-14 and ASEX total scores, where reported, indicated a
range of patients with various levels of sexual functioning upon study entry.
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Table 3. Baseline demographics by study.
Study
Identifier
1.Clayton et
al., 2006 (a)
2.Clayton et
al., 2006 (a)
3.Clayton et
al., 2007
4.Clayton,
Reddy, et
al., 2013;
Dunlop, et
al., 2011
6.Clayton,
Kennedy, et
al., 2013;
Rickels et
al., 2009
7.Clayton,
Kennedy et
al., 2013;
Khan et al.,
2011
8.Clayton,
Tourian, et
al, 2015
9.Clayton,
Gommoll, et
al., 2015;
Mathews et
al., 2015
11.Hewett
et al., 2010
12.Bouleng
er et al.,
2014;

Antidepressant
arms
Buproprion
Escitalopram
Placebo
Buproprion
Escitalopram
Placebo
Duloxetine
Escitalopram
Placebo

Mean
age

Mean
%
Mean
HAM-D
Women MADRS
(b)

Mean
CSFQ-14

Mean
ASEX

35.7

62.0

-

24

51.5

-

36.6

58.0

-

23

53.4

-

42.2

63.5

-

18

36.0

-

Desvenlafaxine
Placebo

42.5

65.2

31

22

-

18.9

Vilazodone
Placebo

39.9

63.7

31

25

-

19.4

Vilazodone
Placebo

41.7

53.2

32

25

42.8

-

Desvenlafaxine
Desvenlafaxine
Placebo

41.6

57.7

-

24

-

15.2

Vilazodone
Vilazodone
Citalopram
Placebo

41.8

55.7

31

-

41.6

-

44.7

67.0

30

-

36.1

-

46.7

69.6

31

-

-

-

Buproprion
Venlafaxine
Placebo
Vortioxetine
Vortioxetine
Duloxetine
Placebo
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Study
Identifier
Clinicaltrial
s.gov
NCT011409
06
13.Mahable
shwarkar,
Jacobsen,
Chen et al.,
2015
14.Jacobsen
et al., 2015
15.Mahable
shwarkar,
Jacobsen,
Serenko et
al., 2015
16. F1JMCHMATa,
2004
17. F1JMCHMATb,
2004
18. F1JMCHMAYa,
2004

Antidepressant
arms

Mean
age

Mean
%
Mean
HAM-D
Women MADRS
(b)

Mean
CSFQ-14

Mean
ASEX

Vortioxetine
Vortioxetine
Duloxetine
Placebo

42.9

72.0

32

-

-

-

Vortioxetine
Vortioxetine
Placebo

42.8

70.1

32

-

-

-

Vortioxetine
Vortioxetine
Placebo

45.0

67.5

34

-

-

-

43.7

65.6

22

18

-

17.9

40.5

64.0

23

18

-

16.1

42.9

74.2

22

20

-

19.7

Duloxetine
Duloxetine
Paroxetine
Placebo
Duloxetine
Duloxetine
Paroxetine
Placebo
Duloxetine
Duloxetine
Paroxetine
Placebo

MADRS = Montgomery–Åsberg Depression Rating Scale; HAM-D = Hamilton Depression Rating Scale;
CSFQ-14 = Changes in Sexual Functioning Questionnaire; ASEX=Arizona Sexual Experiences Scale.
(a) Two studies of identical design were reported in the same publication.
(b) The 17-item HAM-D was used for assessment of depressive symptoms in these studies.
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Assessment of Risk of Bias
Each study was assessed for risk of bias utilizing the Cochrane Collaboration’s tool as outlined
in Table 1. All studies evaluated had low risk for bias on all domains with the exception of one
study evaluating desvenlafaxine (Clayton, Tourian et al., 2015), for reporting bias. The
publication indicated that the ASEX total scores were only reported for patients who had been
sexually active in the past week. Most depressed patients have some level of sexual dysfunction,
so this reduced the sample size to 422 from 907 patients. The full 907 patients were evaluated in
assessment of odds ratios. The article stated that the results of the subgroup for change scores
was consistent with the analysis done for all patients; however, those data were not reported.
Although reporting bias cannot be ruled out, the odds ratio data, which contained the entire
sample, was consistent in direction and by sex with the standardized mean effect scores. Thus,
the determination was made to include these data.
Assessment of Publication Bias
Publication bias was evaluated through the use of funnel plots. Publication bias stems from
failing to detect unpublished studies, which are more likely to have unfavorable results, and/or
may have small samples with greater variance, and can substantially bias effect size estimates.
The majority of the studies included were published; however, data from 7 of the 17 studies
came from unpublished sources, ether partially or entirely (Table 2). Of the 17 included studies,
9 were authored by Anita Clayton, MD. Since this meta-analysis included only studies which
utilized ASEX or CSFQ, it is not unusual for Clayton to be the author on many publications as
she developed the CSFQ. The ASEX is an older tool and has been adopted in more studies in the
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past, but not necessarily with inclusion of the scale developer. The ASEX and CSFQ-14 were
both included in large studies.
The smallest unpublished studies included in this analysis were obtained from the Lilly
website and included paroxetine and duloxetine. The samples sizes per arm ranged from 44 to
59, so were not unusually small. The funnel plots for effect sizes (Figure 2) and odds ratios
(Figure 3) are presented below. In fact in Figure 2, two observations (observation 20
corresponding to duloxetine 80 mg in unpublished study 16, and observation 40 corresponding to
paroxetine 20 in unpublished study 18, Lilly studies) are shown to have higher variances.
However the sample sizes are not particularly small, so the data were included. In Figure 3, the
funnel plot for logged odds ratios, observation 4 corresponding to desvenlafaxine 50 mg in study
4 has a higher variance compared to other observations, but the sample size was relatively large
(N=239), so the data were included. It should be noted that all of the publications that met
criteria were funded by pharmaceutical companies. Individual sponsored studies tend not to be
double-blinded, placebo-controlled studies that utilize validated sexual functioning
questionnaires. Because no non-pharmaceutical funded studies met eligibility criteria, it is not
known whether studies conducted similarly by individuals outside the pharma industry would
have yielded different results in this analysis.
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Figure 2. Funnel Plot for Sexual Functioning Standardized Mean Effect Sizes, Both Sexes

Figure 3. Funnel Plot for Sexual Functioning Logged Odds Ratios, Both Sexes

43
Assessment of Outliers
The distributions of mean effect sizes (75 cases) and logged odds ratio effect sizes (28 cases)
were examined for outliers. Outliers were defined as values that fell more than three interquartile
ranges (IQR) above the 75th percentile or below the 25th percentile of the distribution (Tukey,
1977). No outliers were identified in the logged odds ratio effect size distributions. One outlier
was identified in the mean effect size distribution, paroxetine 20 mg in men from the Lilly study
18. Based on the literature, men taking paroxetine report more negative sexual side effects
compared to women in general. Because of the possibility of gender effects, the data for this
observation was included without adjustment.
Effects on Sexual Functioning of Antidepressants versus Placebo
Standardized mean effect sizes for each antidepressant were calculated for 13 of the 17 studies.
Four of the studies did not provide sufficient data to calculate mean effects, e.g., study did not
report standard deviations or standard errors, and attempts to obtain data were not successful.
Odds ratios for developing sexual dysfunction versus placebo were calculated for 9 of the 17
included studies based on available data. Odds ratios were only calculated for studies that
provided normal or abnormal sexual dysfunction data that were calculated based on the accepted
definition for the ASEX or CSFQ-14 scales.
Standardized Effect Sizes for Mean Change Scores
Standardized effect sizes were calculated based on change scores (mean gains) for placebo
and antidepressant in the 13 studies where data were reported. Table 4 lists the standardized
mean effect sizes, standard errors, CIs, the Q statistic and its significance for each antidepressant
versus placebo. There were insufficient eligible studies to calculate reliable mean effect sizes by
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dose and antidepressant. Therefore, effect sizes were calculated within study by dose and pooled
to create the mean effect size for that antidepressant, as long as the dose was in the approved
therapeutic range. Standardized effect sizes by subscales or single items were also not calculated
due to insufficient sample size. The Q statistic was calculated to determine if there was
significant heterogeneity of variance. The Q statistic could not be calculated for comparisons
between citalopram versus placebo, or for venlafaxine versus placebo because only one study
each was eligible for inclusion in the analysis. Some subgroups by gender included only one
study as well, so the Q statistic was not calculated (see Table 4).

Table 4. Mean Standardized Effect Sizes for Each Antidepressant by Sex
Antidepressant
Comparison

Doses
(mg)

Buproprion XL
Citalopram
Citalopram
Citalopram

NumEffect
ber
Size (a)
studies
3
0.034
1
-0.087
1
-0.117
1
-0.062

Sex

Scale

150 – 450
40
40
40
50 and
100
50 and
100
50 and
100

Both
Both
Men
Women

CSFQ
CSFQ
CSFQ
CSFQ

Both

ASEX

3

Men

ASEX

Women

ASEX

Duloxetine (b)

40-120

Both

Duloxetine

40-120

Men

Duloxetine

40-120

Women

Escitalopram
Escitalopram
Escitalopram
Paroxetine

20
20
20
20

Both
Men
Women

ASEX,
CSFQ
ASEX,
CSFQ
ASEX,
CSFQ
CSFQ
CSFQ
CSFQ

Both

Paroxetine

20

Paroxetine

20

Desvenlafaxine
Desvenlafaxine
Desvenlafaxine

SE

Q

Significance
CI Low
of Q

CI High

0.042
0.062
0.095
0.082

0.200

0.905
-

-0.049
-0.208
-0.304
-0.222

0.117
0.034
0.070
0.099

0.025

0.043

3.305

0.192

-0.060

0.110

3

-0.095

0.066

0.136

0.934

-0.224

0.034

3

0.086

0.066

0.937

0.626

-0.044

0.215

9

-0.018

0.034

22.16

*0.005

-0.085

0.048

4

-0.028

0.083

1.717

0.633

-0.191

0.135

4

-0.080

0.059

3.312

0.346

-0.194

0.035

3
1
1

-0.190
-0.080
-0.290

0.046
0.132
0.099

0.061

0.970
-

-0.280
-0.338
-0.483

-0.101
0.177
-0.097

ASEX

3

-0.169

0.073

1.152

0.562

-0.312

-0.027

Men

ASEX

1

-0.529

0.226

-

-0.972

-0.085

Women

ASEX

1

-0.148

0.153

-

-0.448

0.151
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Antidepressant
Comparison

Doses
(mg)

Sex

Scale

Venlafaxine

75-150

Both

Vilazodone

20-40

Both

Vilazodone

20-40

Men

Vilazodone

20-40

Women

Vortioxetine
Vortioxetine
Vortioxetine

10-20
10-20
10-20

Both
Men
Women

CSFQ
ASEX,
CSFQ
ASEX,
CSFQ
ASEX,
CSFQ
ASEX
ASEX
ASEX

NumEffect
ber
Size (a)
studies
1
0.041

SE

Q

0.064

Significance
CI Low
of Q

CI High

-

-0.084

0.167

4

-0.015

0.032

1.133

0.769

-0.077

0.046

4

-0.144

0.048

1.120

0.772

-0.238

-0.049

4

0.048

0.042

2.754

0.431

-0.033

0.129

8
6
6

0.046
0.113
0.018

0.028
0.066
0.039

4.838
1.715
3.165

0.680
0.887
0.675

-0.008
-0.016
-0.057

0.100
0.241
0.094

CSFQ = Changes in Sexual Functioning Questionnaire; ASEX = Arizona Sexual Experiences Scale; ES = effect size; SE = standard error; Q = the Q statistic;
CI = confidence interval
(a) Decreases indicate worsening of sexual functioning.
(b) The Q statistic for heterogeneity of variance was significant for the standardized mean effect size for both sexes combined. I2 statistic for this effect size and
was 59%.
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Random effects models were planned to account for heterogeneity between studies; however,
in many cases the number of studies for each antidepressant was too small to calculate a reliable
random variance component (see Table 4). In cases where there were 3 or more comparisons,
random effects weighted mean effect sizes and 95% confidence intervals for each study were
calculated. A total of 15 comparisons included 3 or more studies and of these, only 3
comparisons had population variance components that were different than 0. These comparisons
were for desvenlafaxine versus placebo, and for duloxetine versus placebo for both sexes
combined, and for duloxetine versus placebo for women. Overall there were no directional
changes in the point estimates for random effects weighted means for these 3 comparisons.
Arguably, comparisons that include even 3 studies are likely to be too small to calculate random
effects variance, and in fact most of the random variance components in these cases were
negative, thus 0.
The studies included in this meta-analysis were very similar in conduct due to the strict
inclusion criteria, e.g., randomized, placebo-controlled, acute MDD population, similar age
range and use of validated sexual functioning scale; therefore, it is appropriate to present the data
using a fixed-effect model.
The standardized mean effect size, standard error, Q statistic and its significance, and 95%
confidence intervals were also calculated for each study (see Appendix C). The mean effect sizes
were calculated by combining all active arms within the study, if more than one was included,
compared with placebo. Effect sizes were generally small with approximately half were negative
and half positive. Because antidepressants are known to have varying effects on sexual
functioning, from minimal (e.g., buproprion) to significant (e.g., paroxetine), the overall effect
sizes by studies was not particularly informative as many included more than one antidepressant.
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Figures 4-6 plot the mean standardized effect sizes for each antidepressant versus placebo for
both sexes combined and by sex.
Figure 4. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus
Placebo, Both Sexes Combined

Worse than Placebo

Better than Placebo

Figure 4 shows forest plots for each antidepressant versus placebo for both sexes combined.
Only one comparison has significant heterogeneity (Q=22.16; p=0.005): duloxetine, both sexes
combined (see Table 3). The I2 statistic was calculated (59%) for this effect size. Given that the
I2 assessment for heterogeneity was greater than 50%, the individual effect sizes for this
comparison were evaluated. The comparison between duloxetine and placebo included the
highest number of studies in this analysis, which may contribute to the larger range of effect
sizes. In addition, this comparison included several dose groups for duloxetine (40 mg, 60 mg,
80 mg and 120 mg daily), and the level of sexual dysfunction may be dose-dependent. Review of
the individual effect sizes showed that typically lower dose studies with duloxetine had less
negative effects; however, it also appeared to be related to gender. Citalopram, duloxetine,
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escitalopram, paroxetine and vilazodone have point estimates that are worse than placebo;
however, escitalopram and paroxetine are the only antidepressants that are significantly worse
than placebo for both sexes combined. The point estimate for citalopram is somewhat higher, but
the difference is not significant. The remaining antidepressants do not differ significantly versus
placebo when both sexes are combined.
Mean effect sizes were calculated by sex as it was suspected to be a moderator of sexual
dysfunction and antidepressant. Figures 5 and 6 show forest plots for each antidepressant for
which data by sex were available. The Q statistic was not significant for any antidepressant
comparison for the subgroup gender. In men Figure 5), significant differences are found between
paroxetine and placebo, similar to both sexes combined, but while the point estimate for
escitalopram is worse than placebo, it is not significantly different. However, in men, vilazadone
is significantly worse than placebo, but the confidence intervals are very narrow and the point
estimate is similar to desvenlafaxine and citalopram, which are not significantly worse than
placebo. The relatively narrow confidence intervals should be taken into consideration when
assessing the clinical relevance of the significance of this effect.

50
Figure 5. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus
Placebo, Men

Worse than Placebo

Better than Placebo

In women (Figure 6) escitalopram is the only antidepressant significantly worse than
placebo; however, point estimates for paroxetine, citalopram and duloxetine are worse than
placebo, but not significantly. The confidence intervals for the point estimate for paroxetine are
wide for both men and women; however, it is clear that sexual functioning for both men and
women on paroxetine is worse than placebo (even in women where the CI does not cross 0).
While duloxetine was not significantly worse than placebo in men or women, the point estimate
for women was worse than for men, which likely contributed to the heterogeneity in the
combined sex group where the Q statistic was significant.
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Figure 6. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus
Placebo, Women

Worse than Placebo

Better than Placebo

Finally, Figure 7 shows the standardized effects sizes for each antidepressant versus placebo
by men and women, and by combined sexes together in one figure. Gender differences are most
striking for paroxetine and escitalopram. Men are more negatively impacted with treatment of
paroxetine than women, but women are more negatively impacted by treatment with
escitalopram than men.
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Figure 7. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus
Placebo, by Sex

Worse than Placebo

Better than Placebo

Odds Ratios for Developing Sexual Dysfunction
Odds ratios were calculated from the proportion of patients with and without sexual
dysfunction, per ASEX or CSFQ-14 scale definition, at study endpoint. Table 5 lists the mean
standardized odds ratios, standard errors, CIs, the Q statistic and its significance for each
antidepressant versus placebo. There were insufficient eligible studies to calculate reliable mean
effect sizes by dose and antidepressant. Therefore, effect sizes were calculated within study by
dose and pooled to create the mean effect size for that antidepressant, as long as the dose was in
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the approved therapeutic range. The Q statistic was not significant for any comparison for sexes
combined or for the gender subgroups.
Similar to the mean effect size calculation, calculation of random effects weighted odds ratios
and 95% confidence intervals for each study were planned if sufficient comparisons existed.
About half of the comparisons had less than 3 studies, indicating accurate calculation of the
population variance would be difficult or not possible. A total of 6 comparisons included 3 or
more studies and of these, only one (desvenlafaxine versus placebo for both sexes) had a
calculated population variance different from 0; therefore, random effects weighted odds ratios
were not calculated. As discussed previously, study characteristics were similar enough to
support effect size calculations using fixed-effect model.
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Table 5. Mean Standardized Odds Ratios for Antidepressant by Sex
Sex

Scale

N

Mean
SE
OR (a)

Citalopram
Citalopram
Citalopram
Desvenlafaxine
Desvenlafaxine
Desvenlafaxine

Both
Men
Women

CSFQ
CSFQ
CSFQ

1
1
1

0.275
0.393
0.164

0.197
0.312
0.259

-

Significance
of Q
-

Both

ASEX

3

0.024

0.103

4.205

Men

ASEX

1

0.149

0.430

Women

ASEX

1

0.682

Duloxetine

Both

Escitalopram
Paroxetine
Vilazodone

Both

Vilazodone

Men

Vilazodone

Women

Vortioxetine

Both

Antidepressant

Q

CI
Low

CI
High

-0.111
-0.219
-0.343

0.661
1.005
0.671

0.122

-0.179

0.226

-

-

-0.693

0.991

0.298

-

-

0.098

1.265

3

0.346

0.105

1.788

0.409

0.140

0.553

Both

ASEX
CSFQ
CSFQ

1

0.687

0.265

-

-

0.168

1.206

Both

ASEX

1

0.545

0.151

-

-

0.250

0.841

3

0.105

0.100

0.167

0.920

-0.091

0.301

3

0.349

0.156

0.095

0.953

0.043

0.655

3

-0.088

0.132

0.189

0.910

-0.347

0.171

6

0.076

0.104

2.513

0.775

-0.128

0.279

ASEX
CSFQ
ASEX
CSFQ
ASEX
CSFQ
ASEX

CSFQ = Changes in Sexual Functioning Questionnaire; ASEX = Arizona Sexual Experiences Scale; OR = odds
ratio; SE = standard error; Q = the Q statistic; CI = confidence interval
(a) Positive values indicate greater odds of developing sexual functioning compared to placebo.

Figures 8 and 9 show the odds ratio for developing sexual dysfunction by antidepressant
compared to placebo. With both sexes combined, the odds of developing sexual dysfunction with
paroxetine, escitalopram and duloxetine are significantly worse than placebo; however, the
confidence intervals for duloxetine are narrow; therefore, more emphasis should be placed on the
relative risk.
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Figure 8. Odds Ratios of Developing Sexual Dysfunction, Antidepressant versus Placebo, Both
Sexes Combined

Less than Placebo

Greater than Placebo

Odds ratios by sex could not be calculated for all antidepressants included in the overall due
to insufficient data presented in publications. Where data were available, the odds of developing
sexual dysfunction versus placebo by sex were calculated and are presented in Figure 9. Gender
differences are apparent with desvenlafaxine (worse in women) and vilazodone (worse in men).
In most cases the results are consistent as expected from the standardized mean effect sizes with
the exception of desvenlafaxine, which is worse in men based on total score effect sizes and
contrasts with the odds ratios. As only one study contributed to the desvenlafaxine data, the
conflicting results could be due to the smaller sample.
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Figure 9. Odds Ratios of Developing Sexual Dysfunction, Antidepressant versus Placebo, by Sex

Less than Placebo

Greater than Placebo

CHAPTER FIVE
DISCUSSION
The aim of this meta-analysis was to evaluate treatment-associated sexual dysfunction with
second generation antidepressants utilizing studies that collected sexual functioning data via
validated prospective questionnaires. It also included more recently approved antidepressants not
found in previous meta-analyses, i.e., vilazodone and vortioxetine (‘atypical’ antidepressants).
The results of this meta-analysis confirm that there are differences in the effects of
antidepressants on sexual functioning, and that generally the SSRIs (e.g., citalopram,
escitalopram, and paroxetine) have worse impact on sexual functioning than antidepressants of
other classes, and that ‘atypical’ antidepressants (e.g., buproprion, vilazodone, and vortioxetine)
have less impact on sexual functioning than either SSRIs or SNRIs (e.g., duloxetine,
desvenlafaxine, and venlafaxine).
These results are not surprising given that SSRIs function by increasing serotonin in the
brain, which is diminished in depressed individuals; however, the serotonergic system has an
inhibitory effect on sexual desire, orgasm and ejaculation (Clayton et al., 2016). Antidepressants
that target the norepinephrine, as well as serotonergic systems (SNRIs), or dopaminergic (e.g.,
buproprion) systems have a positive impact on sexual functioning, which may account for the
fewer sexual side-effects. Furthermore, the specific serotonin receptors that are activated have
differential effects on sexual functioning. Some 5-hydroxytriptamine (HT) receptors inhibit
sexual activity, such as 5-HT3, the primary target of SSRIs, while others (5-HT1A) stimulate
sexual functioning. Two of the recently approved antidepressants (vilazodone and vortioxetine)
57
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have activity at the 5-HT1A receptor as well, which may mitigate some of the negative activity
at the 5-HT3 receptor.
This analysis also highlighted some important gender effects on sexual functioning, which
vary by antidepressant. Standardized mean change effect sizes indicated that overall paroxetine
and escitalopram were associated with significantly greater sexual dysfunction compared to
placebo, with the mean effect size for escitalopram being slightly worse than paroxetine. Gender
differences were apparent with these two antidepressants; women had greater sexual dysfunction
with escitalopram, and men had greater sexual dysfunction with paroxetine.
In general, the results of the mean odds ratio analysis confirmed the results of the
standardized mean effect sizes. The odds of developing sexual dysfunction with escitalopram
and paroxetine were significantly worse than placebo; however, each comparison was based on
only one study, while the mean effect sizes were based on three comparisons for each. There was
insufficient data to calculate odds ratios by gender for paroxetine and escitalopram. Interestingly,
the odds of developing sexual dysfunction with duloxetine for both sexes combined was also
significantly worse than placebo based on three comparisons; however, the mean effect size for
duloxetine on any comparison did not differ significantly from placebo. In addition, the point
estimate of the mean effect size for women on duloxetine was numerically worse compared to
men.
As mentioned above, gender differences in the impact on sexual functioning were apparent
for some of the antidepressants evaluated. In addition to paroxetine and escitalopram, significant
differences were found in mean effect size and in the odds ratio between men taking vilazodone
and placebo. However, in these comparisons, which included 4 comparisons for the mean effect
size and 3 comparisons for the odds ratio, the effects for both sexes combined and for women did

59
not differ significantly from placebo. In addition, the odds of developing sexual dysfunction in
women with desvenlafaxine were significantly worse than placebo, but that was not the case for
men. The mean effect sizes for sexual functioning for desvenlafaxine versus placebo were not
consistent with the odds ratios, that is, the trend was opposite although no effect size was
significantly worse than placebo. In this case the odds ratios for sex were based on one
comparison while the mean effect sizes were based on three comparisons; therefore, conclusions
should be made with caution. However, clear gender differences were seen with paroxetine,
escitalopram and vilazodone, which highlights an important consideration that antidepressants
can have differential effects on sexual functioning in men and women.
The results of this meta-analysis add to the body of information in the literature by in some
cases confirming what has been reported, and it others adding with information on newer
antidepressants. The level of sexual dysfunction with paroxetine is generally well known;
however, some analyses have shown escitalopram to have less sexual dysfunction by comparison
to other antidepressants than this analysis (Serretti & Chiesa, 2009), while other analyses
confirm these two SSRIs are associated with worse sexual functioning compared to other
antidepressants (Reichenpfader et al, 2014). This difference could be due to the small sample for
the escitalopram comparison included in this analysis, or may reflect the varying methods of
assessing sexual functioning in the studies included in other meta-analyses.
Few studies have evaluated the effects of antidepressants on sexual functioning utilizing
validated questionnaires. Sexual dysfunction by adverse event reporting was not addressed in
this analysis as it is well documented that spontaneous reporting of sexual dysfunction adverse
events is very low and does not represent true levels of sexual dysfunction. Meta-analyses
conducted to date (Serretti & Chiesa, 2009; and Reichenpfader et al, 2014) have generally cast a
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wider net in order to include as much sexual functioning data as possible. While being inclusive
has merit, it also suffers from increased heterogeneity across studies and brings into question the
robustness of the results. For example, combining studies that do not utilize a validated
questionnaire capable of assessing normal and abnormal sexual functioning with those that do,
relies on greater manipulation of data based on assumptions. Analysis of studies that have
utilized similar measures and procedures can allow for a more straighforward interpretation of
results. Similarly comparisons to placebo are easier to interpret versus multiple comparisons
between one antidepressant and another as in the Reichenpfader analysis. While this analysis had
narrow selection criteria and was therefore less inclusive, the results have fewer confounding
variables, e.g., not based on multiple measures that may not assess the same construct or based
on adverse event reporting only which is known to be inaccurate.
The strict selection criteria resulted in a sample that had little heterogeneity across studies.
Therefore, the use of a fixed effect model for reporting of mean effect sizes and odds ratios was
justified, because the studies were consistent in design charateristics and the results of this
analysis apply to MDD patients treated with antidepressants and are not intended to be
generalized beyond this population. The limited number of studies that utilized validated
questionnaires to assess sexual functioning in a randomized, placebo-controlled fashion, resulted
in a smaller sample size which did not allow for analysis of effects by antidepressant dose or by
sexual functioning subgroups. As research expands and more data is collected in this fashion,
further analyses should be conducted that evaluates dose dependency of antidepressants on
sexual functioning and on various dimensions of the sexual response cylce. Finally, conducting
an analysis of this rigor (meeting the eligibility criteria) in a real-world setting would yield
results that would more closely represent depressed patients receiving antidepressant treatment

61
versus clinical trial patients. To conduct a analysis of this kind would be challenging given that
treatment providers do not typically administer validated sexual functioning questionnaires, and
in cases where this is done, the data may not be accessible for analysis. Education of the
importance of addressing sexual functioning issues in depressed patients, methods to accurately
evaluate sexual functioning, and various treatment options will improve the assessment and
treatment of sexual dysfunction, and hopefully lead to more systematic and accurate evaluation
of antidepressant-associated sexual dysfunction.
Limitations
This meta-analysis has some limiations. There were relatively small number of comparisons for
some antidpressants, as strict study eligibily criteria eliminated a number of studies that did not
include placebo and/or did not include a validated questionnaire. All the eligible studies were
funded by pharmaceutical companies and it is not known if individuals conducting studies
meeting the same criteria would have resulted in different findings. Some commonly used
antidepressants were not represented, such as sertraline, due to studies not meeting criteria. Older
studies tended not to include the CSFQ-14 or ASEX as the use of validated questionnaires is
more recent, and subsequently many of the older SSRIs are not represented. In additon, eligible
studies included patients experiencing actute depression (experiencing a current major depressive
episode). Fewer studies have evaluated the effects of antidepressants on sexual functioning in
patients whose depression symptoms are well-treated. Since sexual dysfunction is associated
with depression even in the absense of antidepressant treatment, depression symptoms are a
confounding effect. Therefore, selecting studies that are similar in inclusion criteria for the
severity of depression helps to reduce the effects of this confounder. Because many of the studies
included more than one active treatment (antidepressant) compared to placebo, multiple
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comparisons to placebo were made in calculating effect sizes within study which intruduces
dependency of effect sizes.

APPENDIX A
CODING MANUAL
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Step 1: Study Identifiers, Study Design, Patient Selection, Sexual functioning assessment.
STUDY IDENTIFIERS
Each study will have its own unique Study identifier (e.g., StudyID 12). If there is more than one
study within the same source (e.g., journal article references multiple studies), then the source
will have multiple study ID numbers, and each study will be coded on separate coding sheets. If
there is more than one reference for a particular research study, then the coding should be done
from the most complete source of data (e.g., publication). If data fields are incomplete using only
one source of data, another data source can be utilized if the criteria are met. Each data source
will have its own unique identifier (e.g., 12.1; 12.2, etc.), but may be coded on the same set of
coding sheets. The relevant fields should be coded from the most appropriate source with the
study ID noted in the margin if one set of coding sheets is used.
If data is missing and there is no coded option for a required field enter NA for not applicable or
UNK for unknown. If entire section is not applicable, leave blank or line through.
[StudyID]_________ If multiple sources, list all here if using one coding sheet. Also, indicate in
margins StudyID for source of data.
[Coder] Coder’s initials:________
[CodDT]_________ (Date coding began)
[QCDT]__________ (only use for recoding or QC review of coding is done)
[CMNTS]: This field used to comment on relevant information that is not captured in other
fields.
[PubYR] Publication: ________ (Year of publication, FDA review or posting of results online)
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[Region] Region study was conducted:
A. United States
B. Europe
C. Asia
D. South Africa
E. Global
F. Other_________________ [Region1]
G. UNK
[PubTyp] Type of publication:
A. Journal article
B. Clinicaltrials.gov
C. Summary Basis of Approval (SBA)
STUDY DESIGN
[Source] Source of data:
A. Single study
B. Pooled studies.
[Rand] Method of study randomization
A. Centralized/IVR/IRT
B. Site
C. UNK
[Bias] Risk of bias in randomization assignments:
A. Low (potential for bias)
B. Unclear
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C. High (bias based on methodology)
[Blind] Blinding method:
A. Double-blind
B. Single-blind
C. None (note this is exclusionary)
[PBO] Was study placebo-controlled?
A. Yes
B. No
[Dur] Treatment duration in weeks _______ (If several, select the acute phase, e.g., 6-12 weeks)
[Visit] Number of study visits during treatment? ___________ (including Baseline)
[Design] Study design:
A. Parallel
B. Active-reference
C. Comparator/head-to-head
[Arms] Number of study arms including placebo______
[STDrug] Name of study drug: ______________________________
[STReg] Regimen (eg QD): ____________________________
[STflex] Fixed or flexible dosing? (do not include titration)
A. Fixed
B. Flexible
C. Dose increase allowed
[STDose1] Dose of study drug: _____________________________mg (if flexible put low dose)
[STDose2] Second dose of study drug: ______________________mg (if flexible put high dose)
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[Titrate1] Was study drug 1 titrated?
A. Yes
B. No
C. NA
[ActDrug] Name of reference or comparator drug, if applicable: _____________________
[ActReg] Regimen (eg QD): ____________________________
[Actflex] Fixed or flexible dosing? (do not include titration)
A. Fixed
B. Flexible
C. Dose increase allowed
[ActDose1] Dose of reference/comparator drug:______________mg (if flexible put low dose)
[ActDose2] Second dose of reference/comparator drug:_________mg (if flexible put high dose)
[Titrate2] Was the reference or comparator drug titrated, if applicable?
A. Yes
B. No
C. NA
[Primary] What was the primary objective of the study?
A. Sexual dysfunction
B. MDD
C. UNK
D. Both
[Outcome] Overall result on the efficacy endpoint:
A. Significant differences found
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B. No significant differences found
C. Mixed
SUBJECT SELECTION CRITERIA
[DX] Patient diagnosis for entry to study:
A. MDD
B. Recurrent MDD
C. Depression not specified per diagnostic criteria
[Status] Depressive episode status:
A. Acute
B. Stable
C. Remitted
[Episode] Criteria for duration of current depressive episode in weeks._______
[AgeGrp] Age group enrolled ______________ E.g., 18+, 18-65, 18-45
[MDREnt] Entry criteria for MADRS, if applicable: ______
[HMDEnt] Entry criteria for HAM-D17, if applicable: ______
[CGIEnt] Entry criteria for CGI-S, if applicable: ______
[AxisIEx] Excluded any other axis I other than MDD?
A. Yes
B. No
[NonRes] Excluded non-responders to treatment?
A. Yes
B. No
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[MedCon] Excluded significant medical conditions?
A. Yes
B. No
[SexDys] Excluded Sexual dysfunction disorders?
A. Yes
B. No
[Sexfxn] Sexual functioning enrollment status
A. All
B. Normal
C. Abnormal
MDD EFFICACY ASSESSMENT
[Effic] Type of efficacy endpoint, if measured:
A. MADRS
B. HAM-D17
C. Other _____________________ [EffScale]
[Effect] Type of treatment effect of therapy reported, if assessed.
A.

Mean change from baseline total score

B.

Mean change from baseline total score, difference to placebo/active

SEXUAL FUNCTIONING ASSESSMENT
[Scale] Scale used to assess sexual functioning:
A. ASEX
B. CSFQ
[Specify] Other: ___________________
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[Version] Version of scale used to assess sexual functioning (e.g., short form, full scale, or
version number)___________
[Subs] Subscales reported?
A. Yes
B. No
[Single] Single items reported?
A. Yes
B. No
[Shift] Shift assessment reported (eg, shift from normal to abnormal functioning)?
A. Yes
B. No
[SDScore] Primary score data reported?
A. Mean change from Baseline total score
B. Mean change from Baseline total score difference to placebo
C. Mean change from Baseline total score difference to active control/reference
D. Shift from normal to abnormal sexual functioning
PATIENT DEMOGRAPHICS TOTAL POPULATION
[TotalN] Total patients randomized _______________ Includes all treatment groups
[FAS] Full analysis set (total patients included in primary analysis) ____________ N for the
primary results often listed in table, note this is not the N for safety set which is usually used for
Baseline characteristics. Demographic data below is usually derived from safety set.
[CmpltN] Number of patients completing study ______________
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[LTFU] Number of patients lost to follow-up ______________
[WDAE] Number of patients who withdrew due to adverse event _________
[Female] Percent Female whole study _____________
[Race…] Percent each
A. Percent Caucasian______[RaceA]
B. Percent Black_______[RaceB]
C. Percent Asian_______[RaceC]
D. Percent Hispanic_______[RaceD]
E. Other______[RaceE]
[AgeMn] Mean age. ____________
[MDEMn] Mean duration of MDE in weeks. _____________
[EpisMn] Mean number of prior episodes. ___________
[MDRMn] Mean baseline MADRS total score. _________
[HMDMn] Mean baseline HAM-D17 total score. ___________
[CGIMn] Mean CGI-S score. __________
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STUDY OUTCOMES: BASELINE CHARACTERISTICS
Use multiple pages to complete this section. Data coded in database as A, B, C, or D then
remaining field name. Pages should be labeled 6A-9A, 6B-9B on coding sheets, etc, based
on response to [Group] below.
[StudyID]: __________ [Coder] Coder’s initials:________
[Group] Study group being coded:
A. Placebo
B. Study drug dose 1 (use if only 1 dose or lower dose)
C. Study drug dose 2 (higher dose if more than 1 dose)
D. Active reference/comparator
[…GrpN] Number of patients included in group. __________ (# included for BL sexual
functioning scores, N usually provided for results)
[…GrpFem] Percent Female in group. _____________
Percent each
A. Percent Caucasian_______ […GrpRacA]
B. Percent Black________ […GrpRacB]
C. Percent Asian_______ […GrpRacC]
D. Percent Hispanic _______ […GrpRacD]
E. Other_______ […GrpRacE]
[…GrpAge] Mean group age. ____________
[…GrpMDE] Mean duration of MDE in weeks. _____________
[…GrpEpis] Mean number of prior episodes. ___________
[…MDRBL] Mean baseline MADRS total score. _________
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[…HMDBL] Mean baseline HAM-D17 total score. ___________
[…CGIBL] Mean baseline CGI-S score. __________
Baseline sexual functioning status
[…BLNorm] Baseline percent normal sexual functioning (both sexes)__________
[…BLNormM] Baseline percent normal sexual functioning male. _________
[…BLNormF] Baseline percent normal sexual functioning female. __________
[…BLAbn] Baseline percent abnormal sexual functioning (both sexes)__________
[…BLAbnM] Baseline percent abnormal sexual functioning male. _________
[…BLAbnF] Baseline percent abnormal sexual functioning female. _________
[…BLSDAE] Baseline sexual dysfunction adverse events (percent) __________
Baseline sexual function scale scores (Score/Standard Deviation/Error)
Enter either SD or SE if provided. Indicate UNK if neither is provided. If SD is provided, leave
SE blank.
[..SFBL] BL Sexual fxn total/mean score (both sexes)_____[..SDBL]___[..SEBL]______
[…SFBLM] BL Sexual fxn total/mean score male _____[..SDBLM]____[..SEBLM]____
[…SFBLF] BL Sexual fxn total/mean score female ____[..SDBLF]____[..SEBLF]_____
Baseline Subscales or sub-items (Score/Standard Deviation/Error) Cross out if NA
Enter either SD or SE if provided. Indicate UNK if neither is provided. If SD is provided, leave
SE blank. Eg for subscale names enter, “Pleasure” or “Desire/Freq,” or “Desire/Int” etc. Order
used should be same order as per the instrument. Enter the N for each subgroup, note that the Ns
may all be the same across each subscale group.
[…SFsub1] Subscale/item name #1_____________________ Grp N: ______[..SFsub1N]
[…Sub1] Subscale/item BL score (both sexes)_______[..SDBL1]______[..SEBL1]_____
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[…Sub1M] Subscale/item BL score male _______[..SDBL1M]______[..SEBL1M]_____
[…Sub1F] Subscale/item BL score female______[..SDBL1F]_______[..SEBL1F]______
[…SFsub2] Subscale/item name #2 ______________________Grp N: _______[..SFsub2N]
[…Sub2] Subscale/item BL score (both sexes)______[..SDBL2]______[..SEBL2]______
[…Sub2M] Subscale/item BL score male______[..SDBL2M]______[..SEBL2M]______
[…Sub2F] Subscale/item BL score female_______[..SDBL2F]______[..SEBL2F]______
[…SFsub3] Subscale/item name #3 _____________________Grp N: ________[..SFsub3N]
[…Sub3] Subscale/item BL score (both sexes)______[..SDBL3]______[..SEBL3]______
[…Sub3M] Subscale/item BL score male ______[..SDBL3M]______[..SEBL3M]______
[…Sub3F] Subscale/item BL score female______[..SDBL3F]______[..SEBL3F]_______
[…SFsub4] Subscale/item name #4 ____________________ Grp N: _________[..SFsub4N]
[…Sub4] Subscale/item BL score (both sexes)_______[..SDBL4]______[..SEBL4]_____
[…Sub4M] Subscale/item BL score male ______[..SDBL4M]______[..SEBL4M]______
[…Sub4F] Subscale/item BL score female_______[..SDBL4F]______[..SEBL4F]______
[…SFsub5] Subscale/item name #5 _____________________ Grp N:________[…SFsubN5]
[…Sub5] Subscale/item BL score (both sexes)______[..SDBL5]______[..SEBL5]______
[…Sub5M] Subscale/item BL score male ______[..SDBL5M]______[..SEBL5M]______
[…Sub5F] Subscale/item BL score female______[..SDBL5F]______[..SEBL5F]_______
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STUDY OUTCOMES: ENDPOINT
Enter endpoint as mean total score if provided. If endpoint score is listed as mean change
from Baseline, or difference to Placebo or active ONLY, the total score should to be
calculated and entered here. Indicate if calculated. If unable to calculate, enter as provided
with note in margin.
[…MDREP] Mean endpoint MADRS total score. _________
[…HMDEP] Mean endpoint HAM-D17 total score. ___________
[…CGIEP] Mean endpoint CGI-S score. __________
[…Rem] Percent remission __________
[…Resp] Percent responders __________
Endpoint sexual functioning status including TESD/shift assessment (line through if not
reported, leave blank). Note that shift analysis includes only subjects who initiate treatment
with Normal sexual functioning and shift to Abnormal.
[…EPNorm] Endpoint percent normal sexual functioning (both sexes)._________
[…EPNormM] Endpoint percent normal sexual functioning male. _______
[…EPNormF] Endpoint percent normal sexual functioning female. _______
[…EPAbn] Endpoint percent abnormal sexual functioning (both sexes).________
[…EPAbnM] Endpoint percent abnormal sexual functioning male. _________
[…EPAbnF] Endpoint percent abnormal sexual functioning female. _________
[…Shift] Percent shift to abnormal sexual functioning (both sexes).___________
[…ShiftM] Percent shift to abnormal sexual functioning Male. _________
[…ShiftF] Percent shift to abnormal sexual functioning Female. _________
[…EPSDAE] Endpoint sexual dysfunction adverse events (percent). __________
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Endpoint sexual function scale scores
[…SFEP] End sexual function total score (both sexes) ________[..SD]_______[..SE]_______
[…SDEPM] End sexual function total score male_______[..SDM]______[..SEM]_____
[…SDEPF] End sexual function total score female ______[..SDF]______[..SEF]______
[…SFChg] Sexual fxn change from BL (both sexes) _______[..SDChg]______[..SEChg]_____
[…SFChgM] Sexual fxn change from BL male_____[..SDChgM]_____[..SEChgM]____
[…SFChgF] Sexual fxn change from BL female _____[..SDChgF]_____[..SEChgF]____
Endpoint Subscales or sub-items (Score/Std Deviation/Error) Cross out if NA
Enter either SD or SE if provided. Indicate UNK if neither is provided. If SD is provided, leave
SE blank. Transfer subscale/item name from Baseline section. Use same order.
[…SFsub1] Subscale/item name #1_______________________(same as BL)
[…Sub1EP] Subscale/item end score (both sexes)_________[..SD1]________[..SE1]_________
[…Sub1EPM] Subscale/item end score male _______[..SD1M]_______[..SE1M]______
[…Sub1EPF] Subscale/item end score female_______[..SD1F]_______[..SE1F]_______
[…Sub1Chg] Subscale change score (both sexes)______ [..SDChg1]______[..SEChg1]_______
[…Sub1ChgM] Subscale Change score male _____[..SDChg1M]_____[..SEChg1M]___
[…Sub1ChgF] Subscale Change score female_____[..SDChg1F]_____[..SEChg1F]____
[…SFsub2] Subscale/item name #2 _______________________(same as BL)
[…Sub2EP] Subscale/item end score (both sexes) ________[..SD2]_______[..SE2]______
[…Sub2EPM] Subscale/item end score male _____[..SD2M]______[..SE2M]_____
[…Sub2EPF] Subscale/item end score female_____[..SD2F]_______[..SE2F]______
[…Sub2Chg] Subscale change score (both sexes) _______[..SDChg2]______[..SEChg2]____
[…Sub2ChgM] Subscale change score male _____[..SDChg2M]_____[..SEChg2M]__
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[…Sub2ChgF] Subscale change score female_____[..SDChg2F]_____[..SEChg2F]____
[…SFsub3] Subscale/item name #3 _______________________(same as BL)
[…SubEP3] Subscale/item end score (both sexes) ________[..SD3]_______[..SE3]________
[…Sub3EPM] Subscale/item end score male ______[..SD3M]_______[..SE3M]_____
[…Sub3EPF] Subscale/item end score female_______[..SD3F]_______[..SE3F]_______
[…Sub3Chg] Subscale change score (both sexes) _______[..SDChg3]______[..SEChg3]______
[…Sub3ChgM] Subscale change score male ______[SDChg3M]______[SEChg3M]____
[…Sub3ChgF] Subscale change score female______[SDChg3F]______[SEChg3F]_____
[…SFsub4] Subscale/item name #4 _______________________(same as BL)
[…SubEP4] Subscale/item end score (both sexes) _________[..SD4]_________[..SE4]________
[…Sub4EPM] Subscale/item end score male _______[..SD4M]_______[..SE4M]______
[…Sub4EPF] Subscale/item end score female_______[..SD4F]_______[..SE4F]______
[…Sub4Chg] Subscale change score (both sexes)________[..SDChg4]______[..SEChg4]______
[…Sub4ChgM] Subscale change score male______[..SDChg4M]____[..SEChg4M]____
[…Sub4ChgF] Subscale change score female ____[..SDChg4F]_____[..SEChg4F]_____
[…SFsub5] Sub-item/ sub scale name _______________________(same as BL)
[…SubEP5] Sub-item/ subscale endpoint score__________SD5_____
[…Sub5EPM] Sub-item/ subscale endpoint score male _________SD5M_____
[…Sub5EPF] Sub-item/ subscale endpoint score female__________SD5F_____
[…Sub5Chg] Sub-item/subscale endpoint change from BL__________SE5_____
[…Sub5ChgM] Sub-item/ subscale endpoint change from BL male ___SE5M___
[…Sub5ChgF] Sub-item/ subscale endpoint change from BL female___SE5F___
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Any data that are not provided, but can be calculated from other data present should be done and
entered. Show calculation on coding sheet, use back or margin. Indicate next to field that data
was calculated, e.g.,“Calc”

APPENDIX B
SEXUAL DYSFUNCTION ASSESSMENT TOOLS
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APPENDIX C
EFFECT SIZES BY STUDY
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Effect sizes by study.
Study
Identifier (a)
1.Clayton et
al., 2006
2.Clayton et
al., 2006
3.Clayton et
al., 2007
4.Clayton,
Reddy, et al.,
2013;
Dunlop, et
al., 2011
6.Clayton,
Kennedy, et
al., 2013;
Rickels et
al., 2009
7.Clayton,
Kennedy et
al., 2013;
Khan et al.,
2011
8.Clayton,
Tourian, et
al, 2015
9.Clayton,
Gommoll, et
al., 2015;
Mathews et
al., 2015
11.Hewett et
al., 2010
12.Boulenge
r et al., 2014
Clinicaltrials
.gov

Significance of
Q

CI Low

CI High

3.171

0.075

-0.185

0.035

0.056

5.212

0.022*

-0.174

0.046

-0.157

0.056

0.710

0.701

-0.266

-0.047

Desvenlafaxine
Placebo

0.129

0.073

-

-

-0.014

0.272

Vilazodone
Placebo

0.027

0.064

-

-

-0.099

0.152

Vilazodone
Placebo

-0.055

0.063

-

-

-0.177

0.068

Desvenlafaxine
Desvenlafaxine
Placebo

-0.033

0.054

0.104

0.747

-0.138

0.073

Vilazodone
Vilazodone
Citalopram
Placebo

0.040

0.036

1.194

0.552

-0.111

0.031

0.031

0.045

0.046

0.830

-0.058

0.120

0.130

0.042

4.262

0.119

0.047

0.213

Antidepressant
arms
Buproprion
Escitalopram
Placebo
Buproprion
Escitalopram
Placebo
Duloxetine
Escitalopram
Placebo

Buproprion
Venlafaxine
Placebo
Vortioxetine
Vortioxetine
Duloxetine
Placebo

Mean
ES

SE

Q

-0.075

0.056

-0.064
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Study
Identifier (a)

Significance of
Q

CI Low

CI High

0.485

0.785

-0.055

0.131

0.056

0.034

0.853

-0.021

0.199

-0.031

0.056

1.74

0.187

-0.140

0.078

-0.183

0.072

2.108

0.349

-0.324

-0.042

-0.080

0.074

0.003

0.998

-0.225

0.066

-0.146

0.072

1.439

0.487

-0.288

-0.005

Antidepressant
arms

Mean
ES

SE

Q

Vortioxetine
Vortioxetine
Duloxetine
Placebo

0.038

0.047

14.Jacobsen
et al., 2015

Vortioxetine
Vortioxetine
Placebo

0.089

15.Mahables
hwarkar,
Jacobsen,
Serenko et
al., 2015

Vortioxetine
Vortioxetine
Placebo

NCT011409
06
13.Mahables
hwarkar,
Jacobsen,
Chen et al.,
2015

16.
F1J-MCHMATa
17.
F1J-MCHMATb
18.
F1J-MCHMAYa

Duloxetine
Duloxetine
Paroxetine
Placebo
Duloxetine
Duloxetine
Paroxetine
Placebo
Duloxetine
Duloxetine
Paroxetine
Placebo

ES = effect size; SE = standard error; Q = the Q statistic; CI = confidence interval
(a) Pooled studies 5 and 10 are not included since mean effect sizes were calculated from the individual studies.
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